Kavin Xavier

Companies hate to admit it, but the road to production-level AI deployment is littered with proof of concepts (PoCs) that go nowhere, or failed projects that never deliver on their goals. In certain domains, there’s little tolerance for iteration, especially in something like life sciences, when the AI application is facilitating new treatments to markets or diagnosing diseases. Even slightly inaccurate analyses and assumptions early on can create sizable downstream drift in ways that can be concerning.